- Report
- October 2023
- 150 Pages
Global
From €4660EUR$4,850USD£3,984GBP
- Report
- March 2024
- 185 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- July 2023
- 150 Pages
Global
From €5717EUR$5,950USD£4,888GBP
- Report
- February 2024
- 250 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- February 2024
- 250 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- February 2024
- 250 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- February 2024
- 250 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- January 2024
- 200 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- February 2024
- 120 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- April 2024
- 190 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- November 2023
- 181 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- October 2023
- 181 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- October 2023
- 190 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- October 2023
- 189 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- October 2023
- 180 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2883EUR$3,000USD£2,464GBP
- Drug Pipelines
- April 2024
- 100 Pages
Global
From €2883EUR$3,000USD£2,464GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,643GBP
Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms.
Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients.
Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more